VANDA Pharmaceuticals - Investor Relations - IR Home

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mihael H. Polymeropoulos, MD, President and CEO of Vanda Pharmaceuticals Inc., to Receive The Physicians Committee for Responsible Medicine Trailblazer Award
WASHINGTON , Dec. 12, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that The Physicians Committee for Responsible Medicine, a nonprofit with more than 12,000 doctor members, will present its inaugural Trailblazer Award to Mihael H.
View HTML
Toggle Summary Tradipitant Effective in Preventing Motion Sickness
WASHINGTON , July 16, 2019 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that tradipitant, a neurokinin-1 receptor antagonist, was effective in treating motion sickness in a clinical study conducted in the Pacific Ocean .
View HTML
Toggle Summary Tradipitant in the Treatment of Gastroparesis: Vanda Presents Clinical Trial Results at DDW 2019
WASHINGTON , May 22, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced the results of the Phase II study of tradipitant in gastroparesis were presented at Digestive Disease Week ® (DDW) 2019 in San Diego , CA.  For more information on DDW 2019, please refer to
View HTML
Toggle Summary Vanda Announces New Study Results Showing a High Degree of Inbreeding in Beagle Dogs
Questions the routine use of dogs in human drug toxicology studies. WASHINGTON , Oct. 23, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced results of a comparative genomics study presented at the 2019 American Society of Human Genetics (ASHG) conference on
View HTML
Toggle Summary Vanda Applauds White House Issuance of Executive Orders Requiring Federal Agencies to be Transparent in Policymaking and Enforcement
WASHINGTON , Oct. 16, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients, urges federal agencies,
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Participation at November 2019 Investor Conferences
WASHINGTON , Nov. 18, 2019 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in November 2019 : The Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19, 2019 .
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Participation at the Jefferies 2019 Global Healthcare Conference
WASHINGTON , May 31, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that Mihael H. Polymeropoulos , co-founder and Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare Conference in New York City on Tuesday, June 4, 2019 .
View HTML
Toggle Summary Vanda Pharmaceuticals Announces the Appointments of a Chief Corporate Affairs and Communications Officer and a Chief Marketing Officer
WASHINGTON , Aug. 21, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients, today announced that it
View HTML
Toggle Summary Vanda Pharmaceuticals Applauds the EPA's Landmark Commitment to Eliminate Animal Testing and Urges the Food and Drug Administration to End Unnecessary and Scientifically Flawed Animal Toxicity Studies
WASHINGTON , Sept. 11, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients, commends the U.S.
View HTML
Toggle Summary Vanda Pharmaceuticals Appoints Anne Sempowski Ward to Board of Directors
WASHINGTON , Oct. 28, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Anne Sempowski Ward has joined the company's Board of Directors, effective October 28, 2019 . Following Ms. Ward's appointment, Vanda's Board of Directors is now comprised of six
View HTML
Copyright © 2005-2020 Vanda Pharmaceuticals Inc. |